INC Research Adds AVOS Life Sciences to Strengthen Strategic and Regulatory Consulting Group
INC Research,
LLC. today announced that it has acquired the team and research products of AVOS Life Sciences. The new division of INC Research, now called AVOS Consulting, delivers strategic, operational and financial analysis to help life sciences companies successfully compete in an increasingly challenging global environment. AVOS will operate as an autonomous division within INC Research reporting directly to the chief executive officer, James Ogle,
“We are very pleased to welcome this esteemed group of experts to the INC Research family,” said Ogle.
AVOS offers independent perspectives on the future business environment for healthcare products and services to pharmaceutical, biotech, device and diagnostic companies. Key executives from AVOS, which includes Neil MacAllister, Keith Ruark, Kathleen Griffin, and David Ewbank, have a solid reputation for providing insights into areas such as healthcare trend assessment, business model development, capital allocation, portfolio optimization, accelerated drug development models and pricing and market access.
In addition to providing consulting expertise, members of the AVOS team will dedicate support to INC Research’s innovative Alliance Partnerships program dedicated to the creation and management of strategic clinical delivery alliances. This new approach to sponsor-CRO relationships is designed to drive maximum value for development programs through resource flexibility, corporate efficiency and risk mitigation.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
